التفاصيل البيبلوغرافية
| العنوان: |
Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. |
| المؤلفون: |
Haidar, Ahmad, Legault, Laurent, Dallaire, Maryse, Alkhateeb, Ammar, Coriati, Adèle, Messier, Virginie, Cheng, Peiyao, Millette, Maude, Boulet, Benoit, Rabasa-Lhoret, Rémi |
| المصدر: |
Canadian Medical Association Journal (CMAJ); 3/5/2013, Vol. 185 Issue 4, p297-305, 9p, 1 Diagram, 2 Charts, 2 Graphs |
| مصطلحات موضوعية: |
PHYSIOLOGICAL effects of glucose, INSULIN, GLUCAGON, ARTIFICIAL pancreases, TYPE 1 diabetes, RANDOMIZED controlled trials, CLOSED loop systems, GLYCEMIC index |
| مستخلص: |
Background: Most patients with type 1 diabetes do not achieve their glycemic targets. We aimed to assess the efficacy of glucoseresponsive insulin and glucagon closed-loop delivery for controlling glucose levels in adults with type 1 diabetes. Methods: We conducted a randomized crossover trial involving 15 adults with type 1 diabetes, comparing standard insulin-pump therapy with dual-hormone, closed-loop delivery. Patients were admitted twice to a clinical research facility and received, in random order, both treatments. Each 15-hour visit (from 1600 to 0700) included an evening exercise session, followed by a medium-sized meal, a bedtime snack and an overnight stay. During visits that involved closed-loop delivery, basal insulin and glucagon miniboluses were delivered according to recommendations based on glucose sensor readings and a predictive dosing algorithm at 10-minute intervals. During visits involving standard insulin-pump therapy (control visits), patients used conventional treatment. Results: Dual-hormone closed-loop delivery increased the percentage of time for which patients' plasma glucose levels were in the target range (median 70.7% [interquartile range (IQR) 46.1%-88.4%] for closed-loop delivery v. 57.3% [IQR 25.2%-71.8%]for control, p = 0.003) and decreased the percentage of time for which plasma glucose levels were in the low range (bottom of target range [< 4.0 mmol/L], 0.0% [IQR 0.0%-3.0%] for closed-loop delivery v. 10.2% [IQR 0.0%-13.0%] for control, p = 0.01; hypoglycemia threshold [< 3.3 mmol/L], 0.0% [IQR 0.0%-0.0%] for closed-loop delivery v. 2.8% [IQR 0.0%-5.9%] for control, p = 0.006). Eight participants (53%) had at least 1 hypoglycemic event (plasma glucose < 3.0mmol/L) during standard treatment, compared with just 1 participant (7%) during closed-loop treatment (p = 0.02). Interpretation: Dual-hormone, closed-loop delivery guided by advanced algorithms improved short-term glucose control and reduced the risk of hypoglycemia in a group of 15 adults with type 1 diabetes. Trial registration: ClinicalTrials.gov, no. NCT01297946. [ABSTRACT FROM AUTHOR] |
|
Copyright of Canadian Medical Association Journal (CMAJ) is the property of CMA Impact Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
